Trump's重大决定: Marijuana is downgraded from Schedule I to Schedule III! Same category as Tylenol pain relievers, no longer classified alongside heroin

President Trump has just announced a historic decision: downgrading cannabis from Schedule I to Schedule III! This means cannabis is no longer considered a top-tier drug with “no medical use and high abuse potential,” but is now classified alongside Tylenol with codeine. Trump stated plainly: “This is common sense.” All 50 states have recognized medical cannabis, and especially amid the opioid crisis, cannabis can serve as a safer alternative to help patients manage severe pain. The most significant implication of this downgrade: it will fully loosen restrictions on medical research, allowing scientists to explore its efficacy and risks in depth. Trump also called on Congress to review the classification of CBD to ensure seniors have access to effective pain relief products. This isn’t a political stunt, but a “common sense” commitment!

Core Details and Concept Comparison of Cannabis Downgrade

Trump emphasized: The facts are clear—cannabis, under strict regulation, has medical value and can especially serve as a safer alternative to deadly opioids.

Why Now? Trump’s “Common Sense” Logic

Trump explained personally:

• Opioid Crisis Background: Opioids are deadly, addictive, causing countless tragedies; cannabis can be a safer substitute to relieve severe pain.
• Dignity for Patients: Having seen cancer patients pass away in immense pain, cannabis can relieve pain while keeping patients alert, preserving dignity, unlike opioids which cause confusion.
• State-Level Reality: 40 states plus multiple regions have already legalized medical cannabis, and the federal classification lags behind reality.
• Promise Fulfillment: “I promised to be a president with common sense, and this is what we’re doing.”

This isn’t radical reform, but a pragmatic adjustment aligned with public opinion and science.

Major Change: Complete Loosening of Medical Research Restrictions

Under the previous Schedule I classification, researching cannabis was extremely difficult—bureaucratic hurdles, limited funding. After the downgrade:

• Scientists can systematically study its efficacy (pain relief, anti-inflammatory, neuroprotection, etc.)
• Explore potential risks and optimal usage protocols
• Accelerate new drug development, possibly leading to more cannabinoid-based therapies

Long-term impact: breakthroughs in medicine, especially for chronic pain, epilepsy, and adjunct cancer treatments.

CBD Classification Review: Opening the Door for Pain Relief in Seniors

Trump also called on Congress to revisit the classification of CBD (extracted from industrial hemp, non-psychoactive):

• Ensure seniors can legally and safely use CBD pain relief products
• Avoid unnecessary regulation that hinders effective therapies

This directly addresses the pain points of the elderly: many rely on CBD to alleviate arthritis, nerve pain, and more.

What Does This Mean for America?

• Medical Progress: From “drug” to “medicine,” a new era of cannabis research begins
• Social Impact: Further destigmatization, potential acceleration of nationwide medical cannabis framework
• Economic Potential: Expansion of legal industries, increased tax revenue and jobs
• Political Signal: Trump’s “common sense governance” style, likely bipartisan support

Trump is fulfilling his promise through action: breaking free from outdated frameworks, aligning with reality and science. This isn’t “legalization,” but “medical recognition”—a huge step grounded in common sense.

What do you think about the cannabis downgrade? Share your thoughts below—take one step, see one step—common sense will eventually prevail!